Why the study?
Does commercially available Poliomyelitis vaccine (Salk Type) demonstrate adequate antigenic potency and safety in vaccinated children?
Population
Vaccinated children
Design
Cohort
Authors
Loading...
Cautious interpretation of early cohort data warranted; leaves open need for updated trials on current vaccine formulations.
Does commercially available Poliomyelitis vaccine (Salk Type) demonstrate adequate antigenic potency and safety in vaccinated children?
The study investigates the antigenic potency and safety of commercially available Salk-type poliomyelitis vaccine in children following the implementation of more stringent safety testing methods in 1956.
Kayo Sunada (1958) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: